A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-05-15
Target enrollment:
Participant gender:
Summary
This study is designed to primarily evaluate the safety and efficacy of U3-1402 in
participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2
prior lines of therapy and will explore clinical benefit according to human epidermal growth
factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.